ST6GAL1 and colon carcinoma: In irinotecan-resistant colon carcinoma, there was a higher percentage of CD133+/ALDH1+ CSCs, accompanied by an elevation in the ST6Gal-I level and Fas receptors α2,6-sialylation, whereas the depletion of ST6Gal-I dramatically reduced the enriched CSC subpopulation within the chemoresistant cells [7].